Skip To Main Content
Angus Liu on Muck Rack

Angus Liu

Verified
Washington, D.C.
As seen in: Fierce Biotech, Fierce Pharma, Financial Times, Questex Media Group, EIN News, Genetic Literacy Project, NewsBreak, Fierce Healthcare, The Top Line, fiercebiotechresearch.com, Friends of Cancer Research, Pharmaceutical Intelligence, Dagens Pharma, Cyber Era and
Biopharma reporter @FiercePharma & @FierceBiotech. Medill MSJ 16
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Angus

Contact Angus, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Daiichi Sankyo flags accounting error, as shares tank despite revenue beat

|
By Angus Liu Verified
| Fierce Pharma Verified
A Daiichi Sankyo quarterly report that should have celebrated strong commercial execution was instead derailed by an accounting error and manufacturing losses. During its earnings call Friday, Daiichi disclosed that the company had missed 29 billion Japanese yen ($182 million) in selling, general and administrative expenses (SG&A) in its fiscal year 2025 report, which covers the 12 months ended in March 2026.
Open in Who Shared View Duplicates (2) Issue with article?

Fierce Pharma Asia—Legend CEO exits; Merck’s hush-hush PD-1xVEGF plan; Otsuka’s novel ADHD nod

|
By Angus Liu Verified
| Fierce Pharma Verified
Legend Biotech's Ying Huang, Ph.D., resigned after a six-year stint as CEO. Merck briefly posted—and then quickly deleted—a clinical trial plan to test its PD-1xVEGF bispecific in combination with its Kelun-partnered TROP2 ADC. The FDA approved a new class of ADHD therapy in Otsuka's Simtriyo. And more. 1. Legend Biotech CEO abruptly steps down without permanent replacement Legend Biotech’s CEO, Ying Huang, Ph.D., has resigned.
Open in Who Shared Issue with article?

Alnylam shares tank 29% as Amvuttra disappoints with ATTR outlook cut for 2026

|
By Angus Liu Verified
| Fierce Pharma Verified
Alnylam Pharmaceuticals’ stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a lowered full-year forecast triggered renewed fears over the transthyretin amyloidosis (ATTR) franchise. It was the first quarter Amvuttra sales crossed the $1 billion mark, but its $1.01 billion haul missed analysts’ expectations by 4%. In the U.S., the RNA interference therapy brought in $809 million, or 2% below consensus.
Open in Who Shared Issue with article?
See all 3,883 licensed articles (4,976 Total)